NCT02100579

Brief Summary

Total knee arthroplasty is associated with intense early postoperative pain. Fast track recovery programs including early therapy protocols and early hospital discharge are being implemented at various hospitals. The postoperative analgesic pain regimen should enhance functional recovery in addition to providing efficient analgesia with minimal side effects. Adductor canal blockade is commonly used to provide postoperative analgesia for total knee arthroplasty (TKA) surgery. The investigators hypothesize that an ultrasound guided adductor canal block will lower narcotic consumption and improved overall satisfaction compared to ultrasound guided sham block with normal saline (placebo) for patients undergoing minimally invasive TKA surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Mar 2014

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2014

Completed
24 days until next milestone

First Submitted

Initial submission to the registry

March 25, 2014

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 1, 2014

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2015

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2015

Completed
11 months until next milestone

Results Posted

Study results publicly available

November 2, 2016

Completed
Last Updated

July 11, 2017

Status Verified

June 1, 2017

Enrollment Period

1.6 years

First QC Date

March 25, 2014

Results QC Date

September 14, 2016

Last Update Submit

June 14, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Opioid Consumption (mg morEq)

    Opioid consumption (morphine equivalents)

    36 hours

Secondary Outcomes (2)

  • Visual Analog Scale Pain Score

    Pain burden at 36hr

  • Length of Hospitalization

    0 to 192 hours

Study Arms (2)

Active Group

ACTIVE COMPARATOR

Ultrasound-guided adductor canal blockade with 10 ml of 0.25% bupivacaine

Drug: Bupivacaine

Control Group

PLACEBO COMPARATOR

Ultrasound-guided sham block with 10 ml of preservative free normal saline

Drug: Preservative free normal saline

Interventions

10 ml of 0.25% bupivacaine

Also known as: Sensorcaine
Active Group

10 ml of preservative free normal saline

Also known as: 0.9% sodium chloride
Control Group

Eligibility Criteria

Age40 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Participants 40 to 75 years old who are presenting for minimally invasive total knee arthroplasty under spinal anesthesia

You may not qualify if:

  • Patient refusal
  • American Society of Anesthesiologists physical status classification of 4 or higher
  • Pre-existing neuropathy in the femoral or sciatic distribution
  • Coagulopathy
  • Infection at the site
  • Chronic opioid use (greater than 3 months)
  • Pregnancy
  • Medical conditions limiting physical therapy participation
  • Any other contra-indication to regional anesthesia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Northwestern University Feinberg School of Medicine

Chicago, Illinois, 60611, United States

Location

MeSH Terms

Conditions

Knee Injuries

Interventions

BupivacaineSodium Chloride

Condition Hierarchy (Ancestors)

Leg InjuriesWounds and Injuries

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAminesChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Results Point of Contact

Title
Antoun Nader
Organization
Northwestern University, Feinberg School of Medicine

Study Officials

  • Antoun Nader, MD

    Northwestern University Feinberg School of Medicine

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Anesthesiology

Study Record Dates

First Submitted

March 25, 2014

First Posted

April 1, 2014

Study Start

March 1, 2014

Primary Completion

October 1, 2015

Study Completion

December 1, 2015

Last Updated

July 11, 2017

Results First Posted

November 2, 2016

Record last verified: 2017-06

Data Sharing

IPD Sharing
Will not share

Locations